What is the recommended follow-up schedule and management after coronary stent placement?

Recommended Follow-Up After Coronary Stent

After coronary stent placement, patients should be seen by both their primary care physician and cardiologist at 1 week post-procedure, then every 3-6 months during the first year, with follow-up focused on clinical assessment rather than routine repeat angiography. 1

Antiplatelet Therapy Duration (Most Critical Component)

The duration of dual antiplatelet therapy (DAPT) is the cornerstone of post-stent management and depends entirely on your clinical indication:

For Acute Coronary Syndrome (ACS) Patients:

• DAPT with aspirin 75-100 mg daily PLUS a P2Y12 inhibitor (clopidogrel, prasugrel, or ticagrelor) must continue for at least 12 months 2, 3
• Ticagrelor is preferred over clopidogrel for maintenance therapy 2
• Prasugrel is preferred over clopidogrel in patients without prior stroke/TIA and not at high bleeding risk 2
• After 12 months, continuation beyond may be reasonable if no bleeding complications and not at high bleeding risk 2

For Stable Ischemic Heart Disease (Chronic Coronary Syndrome):

• DAPT for up to 6 months is the default strategy 3
• High bleeding risk patients: discontinue DAPT at 1-3 months, continue single antiplatelet therapy 3
• Low-risk patients: may consider stopping DAPT at 1-3 months 3
• After DAPT period, lifelong aspirin 75-100 mg daily OR clopidogrel 75 mg daily (both equally effective) 3

Special Situations:

• High-thrombotic risk stenting (complex left main, bifurcation, suboptimal result): Consider prasugrel or ticagrelor instead of clopidogrel for first 1-6 months 3
• Patients requiring oral anticoagulation: Stop aspirin at ≤1 week, continue OAC + clopidogrel for 6-12 months depending on ischemic risk, then OAC alone 3

Clinical Follow-Up Schedule

Week 1: First assessment by both primary care and cardiology

• Verify medication compliance (especially DAPT)
• Assess for bleeding complications
• Check access site
• Review cardiovascular risk factors

Months 1-12: Every 3-6 months

• Clinical history focusing on:

  • Recurrent chest pain or anginal equivalents
  • Dyspnea, particularly with exertion
  • Medication adherence (this is predictive of outcomes) 4
  • Any interruptions in DAPT

• Physical examination for:

  • Signs of heart failure
  • New murmurs suggesting complications
  • Peripheral edema

• Risk factor optimization:

  • Blood pressure control
  • Lipid management
  • Diabetes screening (approximately 1/3 have unrecognized diabetes) 4
  • Smoking cessation status

When to Perform Diagnostic Testing

Routine angiography is NOT indicated after successful stent placement 1

Perform stress testing if:

• New or recurrent symptoms develop
• Clinical suspicion of disease progression
• High-risk anatomy (left main, multivessel disease) even without symptoms may warrant consideration 1, 4

Proceed to coronary angiography if:

• Positive stress test
• Symptoms despite medical therapy
• High-risk features on non-invasive testing

Critical Pitfalls to Avoid

1. Premature DAPT discontinuation is the most dangerous error—this dramatically increases stent thrombosis risk, particularly with drug-eluting stents 4

2. Stopping DAPT for minor procedures: Many small surgeries (tooth extraction) can be performed under DAPT 4

3. Triple therapy patients (aspirin + clopidogrel + anticoagulation) require careful bleeding risk monitoring 4

4. Physician instruction quality directly predicts patient compliance—explicit, written instructions are essential 4

Long-Term Management Beyond First Year

• Lifelong single antiplatelet therapy (aspirin or clopidogrel) 3
• Consider adding second antithrombotic agent in patients at high ischemic risk without high bleeding risk 3
• Continue aggressive risk factor modification indefinitely
• Annual cardiology follow-up at minimum

The evidence strongly supports that clinical assessment with history and physical examination is superior to routine angiographic surveillance for detecting disease progression 1. Restenosis detected by routine angiography does correlate with late mortality 5, but symptomatic assessment combined with selective stress testing is the appropriate strategy rather than blanket angiographic screening.